Clinical and Laboratory Effects of Hydroxyurea in Children and Adolescents with Sickle Cell Anemia: A Portuguese Hospital Study

REFERENCES

• Herrick J B. Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. Arch Intern Med 1910; 6:517–521.
   Google Scholar
• Watson J, Stahman A W, Bilello F P. The significance of the paucity of sickled cells in newborn Negro infants. Am J Med Sci 1948; 215:419–423.
   PubMed Web of Science ®Google Scholar
• Charache S, Terrin M L, Moore R D, Dover G J, Barton F B, Eckert S V, McMahon R P, Bonds D R. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med 1995; 332(20):1317–1322. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Ferster A, Vermylen C, Cornu G, Buyse M, Corazza F, Devalck C, Fondu P, Toppet M, Sariban E. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood 1996; 88(6):1960–1964. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kinney T R, Helms R W, O'Branski E E, Ohene-Frempong K, Wang W, Daeschner C, Vichinsky E, Redding-Lallinger R, Gee B, Platt O S, Ware R E. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood 1999; 94(5):1550–1554. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Ferster A, Tahriri P, Vermylen C, Sturbois G, Corazza F, Fondu P, Devalck C, Dresse M F, Feremans W, Hunninck K, Toppet M, Philippet P, Van Geet C, Sariban E. Five years experience with hydroxyurea in children and young adults with sickle cell disease. Blood 2001; 97(11):3628–3632. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Rosse W F, Narla M, Petz L D, Steinberg M H. New views of sickle cell disease pathophysiology and treatment. Hematology (Am Soc Hematol Educ Program) 2000:2–17.
   Google Scholar
• Cokic V P, Smith R D, Beleslin-Cokic B B, Njoroge J M, Miller J L, Gladwin M T, Schechter A N. Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J Clin Invest 2003; 111(2):231–239. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Styles L A, Lubin B, Vichinsky E, Lawrence S, Hua M, Test S, Kuypers F. Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea. Blood 1997; 89(7):2554–2559. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Papassotiriou I, Voskaridou E, Stamoulakatou A, Loukopoulos D. Increased erythropoietin level induced by hydroxyurea treatment of sickle cell patients. Hematol J 2000; 1(5):295–300. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Ohene-Frempong K, Horiuchi K, Bulgarelli W. Hydroxyurea increases Hb F production in children with sickle cell disease. Blood 1993; 82:472a ( abstract).
   Google Scholar
• Oury A P, Hoyoux C, Dresse M F, Chantraine J M. Sickle cell anemia in children: value of hydroxyurea in severe forms. Arch Pediatr 1997; 4(9):839–844. [PUBMED], [INFOTRIEVE], [CROSSREF]
   Google Scholar
• de Montalembert M, Begue P, Bernaudin F, Thuret I, Bachir D, Micheau M. Preliminary report of a toxicity study of hydroxyurea in sickle cell disease. French Study Group on Sickle Cell Disease. Arch Dis Child 1999; 81(5):437–439. [PUBMED], [INFOTRIEVE]
   Google Scholar
• Scott J P, Hillery C A, Brown E R, Misiewicz V, Labotka R J. Hydroxyurea therapy in children severely affected with sickle cell disease. J Pediatr 1996; 128(6):820–828. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Olivieri N F, Vichinsky E P. Hydroxyurea in children with sickle cell disease: impact on splenic function and compliance with therapy. J Pediatr Hematol/Oncol 1998; 20(1):26–31. [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Rogers Z R. Hydroxyurea therapy for diverse pediatric populations with sickle cell disease. Semin Hematol 1997; 34[3 (suppl 3)]:42–47. [PUBMED], [INFOTRIEVE], [CSA]
   Google Scholar
• Jayabose S, Tugal O, Sandoval C, Patel P, Puder D, Lin T, Visintainer P. Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia. J Pediatr 1996; 129(4):559–565. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Ohene-Frempong K, Horiuchi K, Stoeckrlt C. Sustained effect of hydroxyurea on Hb F production in children with sickle cell disease, In: Proceedings of the XX Annual Meeting of the National Sickle Cell Disease Program, Boston, MAUSA, March 18–21, 1995:215, ( abstract).
   Google Scholar
• Koren A, Segal-Kupershmit D, Zalman L, Levin C, Abu Hana M, Palmor H, Luder A, Attias D. Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell β-thalassemia. Pediatr Hematol Oncol 1999; 16(3):221–232. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Lamy S, Braga L, Lavinha J, Gomes da Costa G, Cordeiro Ferreira N. Profilaxia das doenças hereditárias do eritrócito. Acta Med Port 1995; 8(6):355–358. [PUBMED], [INFOTRIEVE], [CSA]
   Google Scholar
• Ware R E, Steinberg M H, Kinney T R. Hydroxyurea: an alternative to transfusion therapy for stroke in sickle cell anemia. Am J Hematol 1995; 50(2):140–143. [PUBMED], [INFOTRIEVE]
   Google Scholar
• Huang Z, Louderback J G, King S B, Ballas S K, Kim-Shapiro D B. In vitro exposure to hydroxyurea reduces sickle red blood cell deformability. Am J Hematol 2001; 67(3):151–156., [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Powars D, Chan L S, Schroeder W A. The variable expression of sickle cell disease is genetically determined. Semin Hematol 1990; 27(4):360–376. [PUBMED], [INFOTRIEVE]
   Google Scholar
• Noguchi C T, Rodgers G P, Serjeant G, Schechter A N. Levels of fetal hemoglobin necessary for treatment of sickle cell disease. N Engl J Med 1988; 318(2):96–99. [PUBMED], [INFOTRIEVE]
   Google Scholar
• Platt O S, Brambilla D J, Rosse W F, Milner P F, Castro O, Steinberg M H, Klug P P. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994; 330(23):1639–1644. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Charache S, Dover G J, Moore R D, Eckert S, Ballas S K, Koshy M, Milner P F, Orringer E P, Phillips G Jr, Platt O S. Hydroxyurea: effects on Hemoglobin F production in patients with sickle cell anemia. Blood 1992; 79(10):2555–2565. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Davies S C, Beuzard Y, Borgna-Pignatti C. The effect of hydroxyurea in sickle cell disease: a European registry of benefits and toxicity (abstract). Hematology 1999; 84:PO-0980.
   Google Scholar
• Claster S, Vichinsky E. First report of reversal of organ dysfunction in sickle cell anemia by the use of hydroxyurea: splenic regeneration. Blood 1996; 88(6):1951–1953. [PUBMED], [INFOTRIEVE], [CSA]
   Google Scholar